CA2010017A1 - Compose pour la reparation et la prevention des lesions fibreuses - Google Patents
Compose pour la reparation et la prevention des lesions fibreusesInfo
- Publication number
- CA2010017A1 CA2010017A1 CA2010017A CA2010017A CA2010017A1 CA 2010017 A1 CA2010017 A1 CA 2010017A1 CA 2010017 A CA2010017 A CA 2010017A CA 2010017 A CA2010017 A CA 2010017A CA 2010017 A1 CA2010017 A1 CA 2010017A1
- Authority
- CA
- Canada
- Prior art keywords
- reparation
- prevention
- composition
- fibrotic lesions
- fibrotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP01-035436 | 1989-02-15 | ||
JP1035436A JPH02215719A (ja) | 1989-02-15 | 1989-02-15 | 線維化病変組織の修復並びに線維化病変の阻止剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2010017A1 true CA2010017A1 (fr) | 1990-08-15 |
CA2010017C CA2010017C (fr) | 1995-09-05 |
Family
ID=12441800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002010017A Expired - Lifetime CA2010017C (fr) | 1989-02-15 | 1990-02-14 | Compose pour la reparation et la prevention des lesions fibreuses |
Country Status (9)
Country | Link |
---|---|
EP (3) | EP0458861B1 (fr) |
JP (1) | JPH02215719A (fr) |
AT (1) | ATE136215T1 (fr) |
AU (1) | AU633541B2 (fr) |
CA (1) | CA2010017C (fr) |
DE (2) | DE69033863T2 (fr) |
DK (1) | DK0458861T3 (fr) |
ES (2) | ES2220612T3 (fr) |
WO (1) | WO1990009176A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
JPH08510251A (ja) * | 1993-05-07 | 1996-10-29 | ビー マーゴリン、ソロモン | 線維症の病変の修復と予防のための組成物および方法 |
EP0813409B1 (fr) * | 1995-03-03 | 2004-05-06 | MARGOLIN, Solomon B. | Traitement des troubles provoques par les facteurs de croissance a cytokine |
AU1226099A (en) * | 1998-09-18 | 2000-04-10 | Mepha Ag | Topical formulation of alkyl-, phenyl-pyridone |
US7867516B2 (en) | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
JP4542743B2 (ja) | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
TW200501952A (en) * | 2003-02-21 | 2005-01-16 | Shionogi & Co | Pirfenidone gel formulations |
WO2004073680A1 (fr) * | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | Onguent du type a repartition des gouttelettes |
US7825133B2 (en) | 2003-11-14 | 2010-11-02 | Shanghai Genomics, Inc. | Derivatives of pyridone and the use of them |
CN1846699A (zh) * | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1-(取代苯基)-5-甲基-2-(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
ATE533486T1 (de) | 2006-06-15 | 2011-12-15 | Shanghai Genomics Inc | Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung |
MX2007006347A (es) * | 2007-05-29 | 2009-02-18 | Cell Therapy And Technology S | Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma. |
NZ599643A (en) | 2007-06-20 | 2013-11-29 | Auspex Pharmaceuticals Inc | Substituted N-aryl pyridinones as fibrotic inhibitors |
CN101918364B (zh) * | 2008-10-21 | 2013-02-13 | 史跃年 | 用于治疗高蛋白尿的药物组合物 |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
EP4059499A1 (fr) * | 2011-01-31 | 2022-09-21 | Avalyn Pharma Inc. | Composés analogues de pyridone et de pirfénidone en aérosol, et leurs utilisations |
US9018232B2 (en) | 2011-03-08 | 2015-04-28 | Auspex Pharmaceuticals, Inc. | Substituted N-aryl pyridinones |
JP5872564B2 (ja) * | 2011-09-14 | 2016-03-01 | 塩野義製薬株式会社 | 吸入用医薬組成物 |
CA2872110C (fr) | 2012-07-18 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Derives heterocycliques azotes et leur application dans des medicaments |
CA2819967C (fr) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Utilisation de pirfenidone en simultanee avec du ciprofloxacin |
EP3083584B1 (fr) * | 2013-12-19 | 2018-02-21 | Sunshine Lake Pharma Co., Ltd. | Dérivés hétérocycliques azotés et leur application dans des médicaments pour le traitement de la fibrose tissulaire |
EP3307714A1 (fr) | 2015-01-26 | 2018-04-18 | Ulkar Kimya Sanayii Ve Ticaret A. S. | Procédé amélioré de synthèse et de purification de pirfénidone |
CA2937365C (fr) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee |
TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
CN109223723B (zh) * | 2017-07-11 | 2021-08-27 | 南京华威医药科技集团有限公司 | 吡非尼酮片剂及其制备方法和用途 |
MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
MX2020005775A (es) * | 2020-07-13 | 2022-01-14 | Centro De Retina Medica Y Quirurgica S C | Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6816241A (fr) * | 1967-12-01 | 1969-06-03 | ||
US3721676A (en) * | 1969-11-12 | 1973-03-20 | Merck & Co Inc | Certain 3-amino-2(1h)pyridones |
US3644626A (en) * | 1969-11-25 | 1972-02-22 | Merck & Co Inc | Novel pyridones in compositions and methods for treating inflammation pain and fever |
US3655897A (en) * | 1971-01-25 | 1972-04-11 | Merck & Co Inc | Anti-inflammatory agents |
US4042699A (en) * | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
CA1049411A (fr) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | Pyridone n-substituee; methode generale de synthese des pyridones |
US4052509A (en) * | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
ZA757570B (en) * | 1974-12-09 | 1977-07-27 | Affiliated Med Res | A useful n-substituted pyridone |
JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
-
1989
- 1989-02-15 JP JP1035436A patent/JPH02215719A/ja active Granted
-
1990
- 1990-01-26 EP EP90903464A patent/EP0458861B1/fr not_active Expired - Lifetime
- 1990-01-26 DK DK90903464.7T patent/DK0458861T3/da active
- 1990-01-26 AT AT90903464T patent/ATE136215T1/de not_active IP Right Cessation
- 1990-01-26 WO PCT/US1990/000449 patent/WO1990009176A1/fr active IP Right Grant
- 1990-02-14 CA CA002010017A patent/CA2010017C/fr not_active Expired - Lifetime
- 1990-02-15 ES ES01107235T patent/ES2220612T3/es not_active Expired - Lifetime
- 1990-02-15 DE DE69033863T patent/DE69033863T2/de not_active Expired - Lifetime
- 1990-02-15 ES ES90301607T patent/ES2163389T3/es not_active Expired - Lifetime
- 1990-02-15 EP EP90301607A patent/EP0383591B1/fr not_active Expired - Lifetime
- 1990-02-15 DE DE69034143T patent/DE69034143T2/de not_active Expired - Lifetime
- 1990-02-15 AU AU49812/90A patent/AU633541B2/en not_active Expired
- 1990-02-15 EP EP01107235A patent/EP1138329B8/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1990009176A1 (fr) | 1990-08-23 |
DE69034143T2 (de) | 2005-06-30 |
ES2163389T3 (es) | 2002-02-01 |
EP1138329B1 (fr) | 2004-06-02 |
JPH02215719A (ja) | 1990-08-28 |
EP1138329A3 (fr) | 2002-04-17 |
AU4981290A (en) | 1990-08-23 |
DE69034143D1 (de) | 2004-07-08 |
EP1138329A2 (fr) | 2001-10-04 |
DK0458861T3 (da) | 1996-08-12 |
JPH0552814B2 (fr) | 1993-08-06 |
EP0383591B1 (fr) | 2001-11-21 |
EP1138329B8 (fr) | 2006-05-17 |
EP0458861B1 (fr) | 1996-04-03 |
EP0458861A4 (en) | 1992-07-08 |
DE69033863T2 (de) | 2002-06-13 |
ES2220612T3 (es) | 2004-12-16 |
AU633541B2 (en) | 1993-02-04 |
EP0383591A2 (fr) | 1990-08-22 |
DE69033863D1 (de) | 2002-01-03 |
ATE136215T1 (de) | 1996-04-15 |
EP0383591A3 (fr) | 1992-01-15 |
EP0458861A1 (fr) | 1991-12-04 |
CA2010017C (fr) | 1995-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4981290A (en) | Composition for reparation and prevention of fibrotic lesions | |
AU6393086A (en) | Thiazole derivative and leukotriene antagonist containing the same as the effective ingredients | |
EP0266576A3 (fr) | Acides carboxyliques de naphtyridines et quinoléines 1-tert-alkyl substituées comme agents antibactériens | |
AU2534092A (en) | 2-substituted saccharin derivative proteolytic enzyme inhibitors | |
HK1003938A1 (en) | Thiazole derivatives as active oxygen inhibitors | |
AU1928188A (en) | Dust suppression methods and compositions | |
AU2152088A (en) | Compositions for topical use having melanin synthesis-inhibiting activity | |
HU9204029D0 (en) | Proteolytic enzym inhibitors | |
EP0157420A3 (en) | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | |
EG18676A (en) | Compound of pyridinesulfonamide used as herbicide | |
EP0299344A3 (en) | Low dust spray-dried emulsion polymerisate and its preparation and use processes | |
SG48298A1 (en) | Saccharin deriatives useful as proteolytic enzymeinhibitors and preparation of | |
EP0339009A3 (fr) | Procédé pour modifier l'efficacité des toxines contre les insectes | |
NZ215868A (en) | Substituted naphthyridine and quinoline derivatives as antibacterial agents | |
AU1539188A (en) | TGF-B2 and novel compositions having anti-neoplastic activity | |
AU7720891A (en) | Novel intermediates for the preparation of novel 5(and/or 6) substituted 2(2-imidazolin-2-yl)nicotinic acids, esters and salts, useful as herbicidal agents | |
AU1559888A (en) | Oncostatin m and novel compositions having anti-neoplastic activity | |
AU8608391A (en) | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | |
AU3329293A (en) | Method of imparting antimicrobial activity to an ophthalmic composition | |
AU4605489A (en) | Enzyme-containing detergent compositions and their use | |
AU1243392A (en) | Prostacycline and carbacycline derivatives as agents for treating feverish complaints | |
ZA855581B (en) | 2-benzyl-4-(4-pyridyl)thiozoles and derivatives therof as immunoregulants | |
ZA871635B (en) | 2-((2-pyridyl)methylsulfinyl)thienoimidazoles and related compounds as antiulcer agents | |
EP0163238A3 (en) | Substituted and bridged pyridines useful as pharmaceutical agents | |
HU896610D0 (en) | Herbicid composition comprising substituted-sulfonyl-urea as active ingredient and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |